A University of Michigan study linked the use of the antibiotic piperacillin/tazobactam in sepsis treatment to a 5% increase in 90-day mortality, underscoring the importance of considering the effects of antibiotics on the gut microbiome when treating life-threatening infections.
“We saw this Zosyn shortage as a one-of-a-kind opportunity to ask whether this antibiotic, which we know depletes the gut of anaerobic bacteria, makes a difference in terms of patient outcomes,” said Robert Dickson, M.D. of the Department of Medicine’s Division of Pulmonary & Critical Care Medicine and Deputy Director of the Weil Institute for Critical Care Research & Innovation.
“These are powerful antibiotics that are administered to patients every day in every hospital nationwide,” said Chanderraj. “Clinicians use them because they are trying to treat every possible pathogen that might be causing their patients’ illness. But our results suggest that their effects on the microbiome might also have important effects on patient outcomes.”that suggested critically ill patients may do worse when given antibiotics that deplete the gut of anaerobes.
Overall, the new findings suggest that treatment with piperacillin/tazobactam instead of cefepime may contribute to one additional death per every 20 septic patients treated.
Technology Technology Latest News, Technology Technology Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SciTechDaily1 - 🏆 84. / 68 Read more »
Source: SciTechDaily1 - 🏆 84. / 68 Read more »
Source: SciTechDaily1 - 🏆 84. / 68 Read more »